Objectives:
To use telemedicine to improve access to care for CF patients in rural settings. We examined 40 patients who have commenced clinic review using telemedicine videoconferencing (TMVC). Patients living in rural areas were targeted for participation. Methods: The TMVC cohort was compared to the non-TMVC CF population at our institution. A standardised remote area classification grading system (Australian Standard Geographical Classification) was used to determine remoteness, classified as R1: Major Cities, R2: Inner Cities, R3: Outer Regional and R4/5: Remote/Very Remote. The Socio-Economic Indexes for Areas (SEIFA) data from the 2011 national census was examined to determine degree of advantage/disadvantage (mean national value 1000). Results: 73% of patients receiving TMVC lived >100 km from specialist centre (mean 197, SD 151), compared to 23% for the general CF population (mean 75km, SD 151). 15% of TMVC patients were from R3, compared to 4% for the comparison group. Mean Index of Relative Socio-Economic Advantage and Disadvantage (IRSAD), and Index of Education and Occupation (IEO) were significantly lower for the TMVC patients than the general CF population; 966 versus 1017 (p < 0.001), and 968 versus 1037 (p 0.001), indicating greater socioeconomic disadvantage. Conclusion: TMVC represents an additional means of outpatient assessment and review. Our institution utilised this technology primarily for patients from rural and remote areas as an alternative means of medical and allied health assessment. Access to healthcare for a group of patients from socially disadvantaged areas has been improved by facilitating specialised outreach using TMVC. Background: There is no standardized patient held records for Cystic Fibrosis (CF) patients in the United Kingdom. After an extensive consultation process with CF children and families, a Personal Hand Held Record (PHHR) was created. The PHHR has eight sections that include personal data, allergies, medicine lists, growth chart, lung function tests, physiotherapy, blood and microbiology results. Objectives: To ascertain the usefulness of a personal record for patients with Cystic Fibrosis and their families. Methods: Young adults and parents were interviewed regarding the usefulness of a PHHR. A national feedback was also sought online at Cystic Fibrosis Trust website. There was an universal positivity towards the need of such record. Once the PHHR was created and rolled on for 1 year, a feedback survey was created. A 15 question survey was created for CF families to fill and return anonymously. Results: 82 Patients were sent the survey. 30 patients have returned the survey to date. 24/30 (80%) found it as extremely useful or useful. Parents whose children were newly diagnosed children with CF were more likely to use it as they felt the need of writing down several informations in one place. 24/30 (80%) used it regularly for the clinic appointments, while 10/30 (33%) used it for holidays as a useful source of information for emergencies. Comments included: 'it is a Godsend' 'this is my memory!'. Conclusion: A concept of PHHR for any chronic disease is very useful. It gives the children and parents control of their disease and provides a single point for recording data and storing documents. This is especially useful when going away or visiting health care professionals. A need for a quick/easy wellness scoring tool for use in a large adult CF unit to improve delivery of care was identified. Objectives: To develop a short and simple questionnaire including aspects of daily life that encompass wellness for routine use across the adult CF population during baseline state and acute exacerbations. Methods: With Alfred Ethics Committee approval a 10 item wellness score was developed using a 1−10 point visual analogue scale (VAS) by members of the CF multidisciplinary team (MDT). The anchors of the VAS were 1 = least well; 10 = most well. Perfect wellness = 100%. Patients enthusiastically completed the score in 1−2 minutes. During baseline state those with mild to moderate lung disease (FEV1 >40%) had mean score 72.4 (13.0) vs those with severe disease (FEV1 <40%) score of 64.5 (11.4), p = 0.093 ns. The score quickly highlights problems that require treatment from the MDT and may assist in deciding when to start and stop therapies. Conclusion: This well accepted quick/easy tool may improve delivery of care to CF in the outpatient and inpatient settings. Using this score we conclude that patients acclimatise to low levels of lung function in advanced disease with reports of relatively high levels of perceived wellness.
